Although the treatment of acute leukemia has improved significantly over the past few decades, the prognosis of acute myeloid leukemia (AML) remains relatively poor. For newly diagnosed patients the complete remission (CR) rate reaches 85% to 90% with standard induction chemotherapy (1). However, about 30% to 50% of the patients that achieve CR relapse from minimal residual disease cells that apparently survived chemotherapy, giving rise to a more resistant leukemia. Resistance to chemotherapy therefore remains a major obstacle in the treatment of AML and novel treatment strategies are warranted (2).